Steve’s undertakes a multi- and inter-disciplinary to investigate the molecular mechanisms underlying platelet activation by tyrosine kinase linked glycoprotein receptors. Steve’s research focuses on the collagen receptor, GPVI, the podoplanin receptor, CLEC-2, the low affinity immune receptor, FcgammaRIIA, and the proteoglycan receptor PEAR1.
Steve uses advanced microscopy (FCS and single molecule), molecular modelling (ODE and agent-based), crystallography, cell line studies and protein phosphorylation to study the mechanisms of receptor activation.
Steve has developed a series of high affinity antibodies and nanobodies that block CLEC-2 and GPVI and is aiming to translate these to early phase clinical trial in thrombo-inflammatory diseases. Steve is working with Pip Nicolson and Mark Thomas in repurposing inhibitors of Syk and Btk as novel antiplatelets in thrombosis and thrombo-inflammatory disorders.
With Pip Nicolson, Steve is also investigating the mechanisms of the thrombosis in patients with vaccine-induced immune thrombosis and thrombocytopenia.
Steve’s research is funded by the BBSRC, British Heart Foundation, EU, MRC, NIHR and Wellcome Trust. Steve is also funded by major Pharma (Sanofi and Novartis) and has a collaboration with Acticor Biotech.